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Primary myeloﬁbrosis is a Philadelphia-negative myeloproliferative neoplasm characterized
by  clonal myeloid expansion, followed by progressive ﬁbrous connective tissue deposition in
the  bone marrow, resulting in bone marrow failure. Clonal evolution can also occur, with an
increased risk of transformation to acute myeloid leukemia. In addition, disabling constitu-
tional  symptoms secondary to the high circulating levels of proinﬂammatory cytokines and
hepatosplenomegaly frequently impair quality of life. Herein the main current treatment
options for primary myeloﬁbrosis patients are discussed, contemplating disease-modifying
therapeutics in addition to palliative measures, in an individualized patient-based approach.anus kinase 2 © 2016 Associac¸a˜o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by  Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license
PI3K and ERK pathways in a ligand-independent way, lead-verview
rimary myeloﬁbrosis (PMF) is a Philadelphia-negative myelo-
roliferative neoplasm (MPN) with a predominant prolifera-
ion of megakaryocytes and granulocytes in the bone marrow
haracterized by an initial proliferative phase, followed by a
eactive deposition of ﬁbrous connective tissue in the ter-
inal phase.1 Bone marrow failure, thromboembolic events
nd transformation to acute myeloid leukemia (AML) are
he main causes of morbi-mortality in PMF, but additional
ymptoms secondary to hepatosplenomegaly and abnormal
lood counts frequently impair quality of life.1,2 The high
irculating levels of proinﬂammatory cytokines also result
n disabling constitutional symptoms (fatigue, weight loss,
ight sweats, fever, pruritus, arthralgias, myalgias).2 Hence,
he decision regarding the best treatment combination in PMF
ust be individualized, taking the symptoms, risks and life
xpectation of each patient into account. Despite the recent
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advances in the development of targeted therapies, allogeneic
hematopoietic stem cell transplantation (allo-HSCT) remains
the only curative option available for PMF.  Evidence on the
main therapeutic options for PMF  will be discussed in this
article.
Molecular  characterization
Although no molecular lesion can speciﬁcally identify PMF,
some recurrent mutations are found and are helpful in the
diagnosis and the prognostic stratiﬁcation of PMF  patients.
JAK2 (Janus kinase 2), MPL (thrombopoietin receptor) and CALR
(calreticulin) genes frequently harbor somatic mutations in
PMF,  which induce the constitutive activation of the JAK-STAT,ade Estadual de Campinas (Unicamp), Rua Carlos Chagas, 480,
ing to increased myeloid proliferation. Approximately 50–60%
of PMF patients exhibit the JAK2V617F mutation.3–5 A gain-of-
function mutation in MPL  (MPLW515K/L), which encodes the
 e Terapia Celular. Published by Elsevier Editora Ltda. This is an
mons.org/licenses/by-nc-nd/4.0/).
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Table 1 – Risk stratiﬁcation of primary myeloﬁbrosis patients according to the Dynamic International Prognostic Scoring
System (DIPSS) and the age-adjusted DIPSS (aaDIPSS)16
DIPSS aaDIPPS
Value Value
0 1 2 0 1 2
Age (years) ≤65 >65 – – –
White blood cell count (×109/L) ≤25 >25 ≤25 >25
Hemoglobin (g/dL) ≥10 <10 ≥10 <10
Peripheral blood blasts (%) <1 ≥1 <1 ≥1
Constitutional symptomsa No Yes No Yes
Risk category Score Survivalb Risk category Score Survivalb
Low 0 not reached Low 0 Not reached
Intermediate 1 1 or 2 14.2 Intermediate 1 1 or 2 9.8
Intermediate 2 3 or 4 4 Intermediate 2 3 or 4 4.8
High 5 or 6 1.5 High >4 2.3
her ta 10% weight loss in six months, night sweats, unexplained fever hig
b Median, years.
thrombopoietin receptor and is a key factor for growth and
survival of megakaryocytes, has been reported in up to 5%
of PMF  cases.6,7 MPL  mutations may occur concurrently with
the JAK2V617F mutation.8 Approximately 60–80% of JAK2 and
MPL  wild type patients harbor CALR mutations.9,10 Additional
mutations in epigenetic regulators, such as TET2,11 ASXL1,12
DNMT3A,13 IDH1/2,14 have been described in MPN patients
at variable frequencies and their prognostic value has been
object of studies.15
Risk  stratiﬁcation
Adequate risk stratiﬁcation in PMF  is essential to establish
the most suitable treatment for a particular patient, taking
the risk-beneﬁt of each approach into account. In this sense,
the Dynamic International Prognostic Scoring System (DIPSS)
for PMF  is widely used in the clinical practice. DIPSS is a
dynamic prognostic model that considers modiﬁcations in the
risk proﬁle after diagnosis and can predict prognosis at differ-
ent stages of the disease (Table 1).16 The age-adjusted DIPSS is
a variation speciﬁcally developed for younger patients (age <65
years), comprising the group that is most commonly suitable
for intensive therapies such as allo-HSCT (Table 1).16
Treatment  options
Hydroxyurea
Hydroxyurea (HU) is a non-alkylating antineoplastic agent
used for cytoreduction in myeloproliferative neoplasms.
Although there are few well designed studies evaluating HU
beneﬁts in myeloﬁbrosis patients, hydroxyurea is frequently
used to attenuate hyperproliferative manifestations related to
PMF.17 In a group of 40 PMF  patients, Martinez-Trillos et al.
showed signiﬁcant response rates, with reductions in consti-
tutional symptoms (55%), symptomatic splenomegaly (45%),
thrombocytosis (40%) and leukocytosis (28%); accentuationhan 37.5 ◦C.
of anemia was the most common adverse event, and was
observed in almost half of the patients.17 When HU resis-
tance/refractoriness is documented in the PMF proliferative
phase, switching from HU to a molecular targeted therapy (i.e.,
JAK1/2 inhibitor) should promptly be considered.18 The crite-
ria for resistance and refractoriness to HU in PMF  patients
have previously been deﬁned by the European LeukemiaNet
consensus.18
Support  therapy
Anemia
Anemia is a frequent manifestation of PMF19 that might
be caused by different interacting factors, such as bone
marrow insufﬁciency (ﬁbrosis), hypersplenism, bleeding, iron
deﬁciency, vitamin B12 or folate deﬁciency, or autoimmune
hemolysis.20,21 Moreover, speciﬁc PMF  treatment with cytore-
ductive drugs (HU)17 and JAK1/2 inhibitors22 can lead to, or
increase, anemia in these patients. Besides correcting the
potentially reversible causes of anemia, some other thera-
peutic possibilities might be considered when anemia is a
disabling symptom. Some of them are discussed below.
a. Androgens
Androgens have been used to treat anemia in PMF  with
variable response rates; most of the studies described results
observed in small cohorts. Danazol, a semisynthetic attenu-
ated androgen that has fewer side effects, results in an anemia
response rate of 30–57% depending on the adopted response
criteria.21,23,24 In a cohort of 50 patients with PMF,  Cervantes
et al.21 described a 30% response rate [deﬁned by transfusion
cessation in transfusion-dependent patients or an increase
in hemoglobin (Hb) >2 g/dL in patients without transfusion
requirements], with a median duration of anemia response
of 14 months. Androgens should not be used in patients with
prostatic symptoms, prostate cancer or moderate to advanced
hepatic disease.
b. Erythropoiesis-stimulating agents
Although recombinant human erythropoietin (EPO) has
been widely used for the treatment of anemia of a variety of
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auses, the experience in PMF  is relatively small and based on
tudies with limited sample sizes. Reported overall response
ates range from 23% to 60%.25–28 Hb <10 g/dL, transfusion
ndependence,25,27 and EPO levels <125 U/L27 are factors that
ight confer a better response to treatment. However, these
ata need to be validated in larger cohorts using uniform
esponse criteria.
c. Immunomodulating drugs
Thalidomide has shown effectiveness in a wide spectrum
f neoplasms due to its anti-angiogenic and immunological
ffects. Previous reports using high doses of thalido-
ide (100–400 mg)  in PMF  have demonstrated encour-
ging responses regarding the improvement of anemia
20%–60%), thrombocytopenia (38%–80%), and splenomegaly
25%–41%).29–32 However, the high level of side effects (somno-
ence, fatigue, edema, constipation, neurological symptoms,
eutropenia) signiﬁcantly reduced tolerability.29,30,32,33 The
se of low doses of thalidomide (50–100 mg)  associated or not
ith prednisone (0.5 mg/kg/day) can decrease toxicity with
imilar response rates.34–36 Lenalidomide, a thalidomide ana-
og, has been described as an additional therapeutic option,
ith response rates ranging from 19–30% for anemia, 0–50%
or thrombocytopenia and 10–42% for splenomegaly,37–39
ccording to the scheduled dose and the response crite-
ia adopted. Recently, Daver et al.40 evaluated the combined
ffect of lenalidomide plus the JAK1/2 inhibitor ruxolitinib
n 31 patients with PMF; however, the study had to be dis-
ontinued prematurely due to the elevated number of drop
uts (23 patients) due to drug toxicity.40 Among the patients
ho  did not require early dose interruption, response rates
ere high (73%), suggesting that additional studies using
ower doses of lenalidomide and ruxolitinib might be of
nterest.40 Moreover, a retrospective study by Jabbour et al.41
hat evaluated three previous phase 2 clinical trials com-
ared the efﬁcacy of thalidomide and lenalidomide-based
herapies, and observed overall response rates of 16% and
4–38%, respectively, according to the International Work-
ng Group (IWG) for Myeloﬁbrosis Treatment and Research
riteria. In addition, lenalidomide plus prednisone improved
esponse duration when compared to both thalidomide and
enalidomide single agent therapies, suggesting that lenalido-
ide plus prednisone might be a reasonable option when
eciding for immunomodulating drugs.41 Pomalidomide is a
otent second-generation immunomodulating drug that has
 better toxicity and safety proﬁle than thalidomide and
enalidomide,42 and has been tested in PMF in few stud-
es with varying results. Anemia response rates ranged from
0–37%,42–47 but increased to 53% in a single report that specif-
cally analyzed the group of JAK2V617F-positive patients with
10 cm palpable splenomegaly and <5% circulating blasts,
ndicating that these factors might be predictors of better
esponse.44
d. Chronic transfusion and iron chelation
For the symptomatic anemic patients that are refractory
o speciﬁc therapies, chronic red blood cell transfusions may
mprove symptoms and quality of life. For the treatment of
econdary iron overload in transfusion-dependent patients
ho  have curative intentions (e.g. bone marrow trans-
lantation) and/or higher life expectations, iron chelation
hould be considered in order to prevent iron-induced organ 1 6;3  8(3):257–263 259
damage. Furthermore, iron chelation may promote an ery-
throid response with increased Hb levels in some PMF
patients,48 albeit additional studies are needed to support this
recommendation.
Splenomegaly
The enlarged spleen is a major source of discomfort and
impaired quality of life in PMF. Constitutional symptoms, pain,
early satiety due to gastric compression, portal hypertension
and cytopenias are frequent ﬁndings in PMF  in the ﬁbrotic
phase.49,50 In PMF patients with an unsatisfactory response
to pharmacological treatment, splenectomy and splenic radi-
ation may be treatment options, as discussed below.
a. Splenectomy
Despite the improvement in perioperative mortality follow-
ing splenectomy observed in the last decades due to better
patient selection, vaccination, antimicrobials and surgical
procedures, splenectomy does not seem to alter patient sur-
vival and disease evolution.49 However, it might be exception-
ally indicated for the palliative control of persistent anemia,
thrombocytopenia, portal hypertension and pain.49,51 In a ret-
rospective analysis of 223 patients submitted to splenectomy
at the Mayo Clinic during a 20-year period, durable remis-
sions in constitutional symptoms, transfusion-dependent
anemia, portal hypertension, and severe thrombocytopenia
were achieved in 67%, 23%, 50%, and 0% of the patients, respec-
tively, with rates of nonfatal complications of 30.5%, including
7.2% of thrombosis, and 8.9% of fatal complications.51 San-
tos et al.52 described, in a cohort of 94 splenectomized PMF
patients, improvements of anemia and thrombocytopenia
in 47% and 66% of the cases, respectively. Thrombosis was
observed in 16% of the patients, and post-operative mortality
was 5%, with a lower overall survival for the patients that were
submitted to splenectomy during disease evolution.52 Since
splenectomy is associated with substantial risks, the proce-
dure should only be considered for selected patients following
stringent criteria including absence of severe comorbidities,
adequate life expectancy, signiﬁcant splenic symptoms that
affect quality of life, and failure of at least one pharmacological
therapy for splenomegaly.49
b. Splenic irradiation
Splenic irradiation is a palliative modality of treatment
considered as an alternative to splenectomy in PMF  patients
that have symptomatic splenomegaly and are ineligible for
surgical procedures. However, although spleen size reduc-
tion and symptom relief are observed in a high proportion
of patients, response to treatment is usually brief and
transient.50,53 The worsening of pre-treatment cytopenias and
the emergence of infectious complications are frequently
found.53
Additional  palliative  measures
Myeloﬁbrosis severely compromises quality of life as a result
of marked splenomegaly, profound constitutional symptoms
and cachexia.54 In a group of 458 patients, including PMF
and post-polycythemia vera (PV)/post-essential thrombocy-
topenia (ET) myeloﬁbrosis, Mesa et al. found an incidence
of 84% for fatigue, 47% for bone pain, 50% for pruritus, 56%
for night sweats and 54% for symptomatic splenomegaly.54
Therefore, adequate symptom control, such as optimized pain
oter.
Although reduction of bone marrow ﬁbrosis after immunosup-
pressive treatment may be observed, the complete resolution
of bone marrow ﬁbrosis is not necessary for the recovery of260  rev bras hematol hem
management and evaluation of nutritional status, are manda-
tory adjuvant therapies.
Interferon
Interferon has been described as a therapeutic option in
the treatment of PMF  patients, though only a limited
number of studies evaluating the effects of interferon in
larger PMF  cohorts are available. Previous studies indi-
cated that recombinant interferon- has the potential to
decrease the proliferation of PMF  neoplastic stem cells with
a signiﬁcant reduction of marrow ﬁbrosis, cellularity and
megakaryocyte density,55,56 which can result in improvements
of splenomegaly and blood counts.56,57 Systemic toxicity
(cytopenias, asthenia, fatigue, myalgia) may limit interferon
use in a proportion of patients; however, most cases can be
manageable with dose reductions.55,56 Larger studies are nec-
essary to fully support interferon use in PMF patients and its
effects on overall survival.
JAK1/2  inhibitors
The activation of the JAK-STAT pathway induced by muta-
tions in JAK2, CALR and MPL genes has a central role
in inducing cell proliferation in PMF,15 making this path-
way a potential target for directed therapies. Ruxolitinib,
the ﬁrst US Food and Drug Administration (FDA)-approved
oral JAK1/2 inhibitor is generally well-tolerated, and signif-
icantly reduces splenomegaly and ameliorates debilitating
myeloﬁbrosis-related symptoms.22,58 An evaluation of the
nutritional status in intermediate-2 or high risk PMF  patients
showed that ruxolitinib signiﬁcantly increased weight and
albumin levels.59 The most common side effects are a dose-
dependent anemia and thrombocytopenia, that are usually
manageable with dose reductions.22,58 A three-year follow up
analysis of the controlled myeloﬁbrosis study with oral JAK
inhibitor (COMFORT-I) – a double-blind, placebo-controlled
trial that previously suggested a survival beneﬁt for the ruxoli-
tinib group58 – reported that ruxolitinib signiﬁcantly improved
quality of life, reduced spleen volume and improved survival
of patients with intermediate-2 or high risk PMF when com-
pared to placebo.60 However, a recent Cochrane meta-analysis
suggested that there is insufﬁcient data for deﬁnitive conclu-
sions regarding the beneﬁts of ruxolitinib on the survival of
PMF  patients.61 Future updates in ruxolitinib studies show-
ing longer follow-up times will be of value to allow deﬁnitive
conclusions regarding survival beneﬁts. In order to identify
genes that may predict response to ruxolitinib in myeloﬁbrosis
patients, Patel et al.62 screened mutations in 28 genes recur-
rently mutated in hematologic malignancies, and found that
patients with ≥3 mutations had poorer responses to ruxoli-
tinib and shorter overall survival.62 Despite other selective JAK
inhibitors having been submitted to clinical trials with promis-
ing results63,64 none have been approved for clinical use until
the present.Bone  marrow  transplantation
Allo-HSCT is currently the only curative treatment option
for myeloﬁbrosis patients. Allo-HSCT should be considered 2 0 1 6;3  8(3):257–263
in intermediate-2/high risk patients, and in patients with
refractory disease, adverse cytogenetics or >2% blasts in the
peripheral blood.65–68 Although age >45 years is described as
an adverse prognostic factor for transplantation in PMF,66 allo-
HSCT can be considered for individuals younger than 70 years
old who have good performance status and no signiﬁcant
comorbidities.65 Previous studies have demonstrated that
unrelated donor, post-transplant transfusion dependence,66
and JAK2V617F levels >1% one month after transplantation67
are prognostic factors that adversely affect overall
survival.
Special  situations
Post-polycythemia  vera  and  post-essential
thrombocythemia  myeloﬁbrosis
PV and ET are MPN  which can evolve to myeloﬁbrosis as a
disease-related complication,69 with an incidence of evolution
to ﬁbrosis over 15 years of 5–14%69,70 and 9.3%,69,71,72 respec-
tively. Post-PV and post-ET myeloﬁbrosis are molecularly
distinct but phenotypically similar to PMF,  with equivalent
clinical courses; for this reason, most clinical trials group
patients of these three disease categories in their cohorts.2
Currently, there are no speciﬁc therapeutics for post-PV and
post-ET myeloﬁbrosis, and these patients should be treated
similarly to PMF patients.2,73
Autoimmune  myeloﬁbrosis
Autoimmune myeloﬁbrosis (AMF) is a benign cause of bone
marrow ﬁbrosis associated with autoimmune disorders, such
as systemic lupus erythematosus, scleroderma, Sjogren’s syn-
drome, Hashimoto thyroiditis, autoimmune hepatitis, and
Evans syndrome.74 AMF can also be found in patients
with no well-established diagnosis of autoimmune disease,
usually associated with elevated titers of antinuclear antibod-
ies, rheumatoid factor, and/or a positive direct antiglobulin
test.74,75 It is characterized by reticulin marrow ﬁbrosis in
the absence of clustered or atypical megakaryocytes or other
clinicopathological features of hematological malignancies.76
AMF  usually responds to corticosteroid therapy with a gen-
erally good prognosis.74,76 A course of prednisone starting
at 1 mg/kg/day and tapered over 1–3 months can result in
complete normalization of peripheral blood counts.76,77 Cases
with partial response to corticosteroids appear to beneﬁt
from the addition of another immunosuppressive agent. In
general, results of steroid therapy have been less impres-
sive in AMF  associated with systemic lupus erythematosus.peripheral blood cytopenias.76 Considering the differences in
treatment and prognosis, the differential diagnosis between
primary myeloﬁbrosis and autoimmune myeloﬁbrosis is
crucial.
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PMF DIPSS risk group
Low
intermediate-1
Intermediate-2
high
Asymptomatic Symptomatic
Watch and wait + +
Symptom-directed treatment
JAK inhibitors Allo-SCT
Treatment failure
Allo-SCT eligible
Disease progression
Age
Comorbidities
Performance status
Patients’ preferences
Figure 1 – Proposed treatment algorithm for primary
myeloﬁbrosis patients according to DIPSS risk groups.
Therapeutic decisions take the risk group and patients’
particularities into account. The palliation of symptoms
needs to be continuously pursued, independently of the
therapeutic choice, and are additive to disease-modifying
treatment, as indicated by the dotted lines. PMF: primary
myeloﬁbrosis; DIPSS: Dynamic International Prognostic
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ransplantation.
reatment  decision  –  when  and  whom?
symptomatic PMF patients in the low and intermediate-1
isk groups according to DIPSS have a long expected survival
nd do not usually require speciﬁc treatment. If symptomatic,
atients in these risk categories can be treated according to
he prevailing symptom, as discussed above. Intermediate-2
nd high-risk DIPSS patients have a shortened survival and
hould be considered for disease-modifying therapies, such
s JAK inhibitors and allo-HSCT, when tolerated; the decision
etween these two options has to be individualized taking
nto account the patient’s age, performance status and prefer-
nces. Combination therapies for the palliation of symptoms,
egardless of the risk group and the prognosis, are beneﬁcial
nd should be implemented to improve patients’ quality of
ife. A treatment algorithm is proposed in Figure 1.
onclusions  and  perspectives
xpressive progression has recently been achieved in the
nowledge of the pathophysiology of primary myeloﬁbro-
is, which has allowed the development of targeted-drugs
hat may alter disease progression. Many  molecule-speciﬁc
rugs are under development or being tested, but could not
e discussed herein due to space limitations. JAK inhibitors
ave shown promising results, though additional studies and
ollow-up time will be of value to further support survival ben-
ﬁts. Currently, allo-HSCT remains the only curative option.
n a patient-based approach, the palliation of the symptoms
s fundamental from diagnosis until end-stage disease.
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